Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Michael Bauml, Tanguy Y. Seiwert, David G. Pfister et al. · Journal of Clinical Oncology · 2017
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks. Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, central review) and safety. Efficacy was assessed in all dosed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status. Results Among 171 patients treated, 75% received two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% were HPV positive. At the time of analysis, 109 patients (64%) experienced a treatment-related adverse event; 26 patients (15%) experienced a grade ≥ 3 event. Seven patients (4%) discontinued treatment, and one died of treatment-related adverse events. Overall response rate was 16% (95% CI, 11% to 23%), with a median duration of response of 8 months (range, 2+ to 12+ months); 75% of responses were ongoing at the time of analysis. Response rates were similar in all HPV and PD-L1 subgroups. Median progression-free survival was 2.1 months, and median overall survival was 8 months. Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab.
Cited by 663 works. doi:10.1200/jco.2016.70.1524
Authors
- Joshua Michael Bauml
- Tanguy Y. Seiwert
- David G. Pfister
- Francis Paul Worden
- Stephen V. Liu
- Jill Gilbert
- Nabil F. Saba
- Jared Weiss
- Lori J. Wirth
- Ammar W. Sukari
- Hyunseok Kang
- Michael K. Gibson
- Erminia Massarelli
- Steven Francis Powell
- Amy Meister
- Xinxin Shu
- Jonathan D. Cheng
- Robert I. Haddad
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial